Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 14/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26692139 | 1.00 | PSMB5 (0.38) | PSMB5PSMB8CA2ANPEPLAP3 | |
| SCHEMBL26692146 | 1.00 | PSMB5 (0.38) | PSMB5PSMB8CA2ANPEPLAP3 | |
| SCHEMBL26692141 | 1.00 | PSMB5 (0.38) | PSMB5PSMB8CA2ANPEPLAP3 | |
| SCHEMBL20764142 | 0.79 | ANPEP (0.50) | PSMB5ANPEPLAP3 | |
| Hydrochloric Acid SCHEMBL26692120 | 0.74 | ANPEP (0.56) | PSMB5PSMB8CA2ANPEPLAP3 | |
| Hydrochloric Acid SCHEMBL31423718 | 0.74 | ANPEP (0.56) | PSMB5PSMB8CA2ANPEPLAP3 | |
| Hydrochloric Acid SCHEMBL26692117 | 0.74 | ANPEP (0.56) | PSMB5PSMB8CA2ANPEPLAP3 | |
| SCHEMBL31423666 | 0.73 | ANPEP (0.37) | PSMB5ANPEPLAP3 | |
| SCHEMBL20401414 | 0.72 | ANPEP (0.42) | ANPEPLAP3 | |
| SCHEMBL20401416 | 0.72 | ANPEP (0.42) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346613-A1 | BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4516796-A1 | BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346613-A1 | BORIC ACID PROTEASOME INHIBITOR AND USE THEREOF | PSMA1, PSMB11, PSMB1 | PSMB5 12/4885PSMB8 20/4885CA2 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.